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2. Objectives
The pathogenesis of hepatitis B is associated with cel-
lular immune responses that aim to remove HBV from 
the body (1). If the resulting cellular immunity is too 
intensive, it can result in the necrosis of many liver cells 
and severe hepatitis. However, it is unknown whether 
HBV-specific or nonspecific cellular immune responses 
immediate the deterioration of CHB.
3. Patients and Methods
3.1. Subjects
We enrolled 255 CHB patients into this study from 
1. Background
Clinically, liver disease can progress into chronic se-
vere hepatitis B in some patients with CHB, even after 
admission and after receiving treatment. It is difficult to 
predict which CHB patients will develop chronic severe 
hepatitis.
Background: It is difficult to predict what type of chronic hepatitis B (CHB) progresses to 
chronic severe hepatitis B.
Objectives: This study aimed to observe changes in the HBV-specific and -nonspecific cell-
mediated immune responses after CHB deteriorates into severe hepatic disease and ex-
plore the significance of such changes.
Patients and Methods: This study aimed to observe changes in the HBV-specific and -non-
specific cell-mediated immune responses after CHB deteriorates into severe hepatic dis-
ease and explore the significance of such changes.
Results:  In 49 of 255 CHB patients (19.22%), the disease developed into chronic severe 
hepatitis (early stage) an average of 10.06 ± 1.73 days after admission. CD4+ and NK cells 
levels in Group A were lower after progression into severe hepatitis than on the second 
day of admission (baseline) (P < 0.01). CD8+ cells and nonspecific CTL levels in Group A 
were higher after progression than at baseline (P < 0.01), and latter was higher than in 
Group B at baseline (P < 0.01); the levels of CD8+ cells and nonspecific CTLs in Group A 
after progression were significantly higher than those of Group B 10 days after admis-
sion (P < 0.01). There were no significant differences in HBV-specific CTL levels in Group A 
before and after progression to severe hepatitis (P > 0.05).
Conclusions: Our results suggest that the immunological pathogenesis of chronic severe 
hepatitis B is related to significant rises in CD8+ and nonspecific CTL levels and that such 
increases predict that the disease will deteriorate into severe hepatitis.
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Jan. 2006 to Aug. 2010. This study was conducted in our 
hospital in Wuxi, China. Diagnoses of CHB and chronic 
severe hepatitis were made per the diagnostic criteria 
in the Program for Prevention and Treatment of Viral 
Hepatitis (2). The requirements for enrollment included 
positivity for HBV DNA (HBV DNA > 103 copies/mL), ala-
nine aminotransferase (ALT) > 2× upper limit of normal 
value, and age over 18 years. Exclusion criteria included 
patients with hepatitis A, C, D, or E infection; a medical 
history of autoimmune disease; alcohol abuse; medi-
cation with hepatotoxic agents; and use of antiviral 
agents, such as nucleoside analogs and interferons, and 
immune-enhancing or immunosuppressive agents, such 
as glucocorticoids.
The 255 CHB patients were divided into two groups. 
Group A consisted of 49 cases whose disease progressed 
to chronic severe hepatitis B; 35 were male (71.45%), 
the average age was 35.68 ± 9.63 years, and the average 
course of illness was 4.27 ± 2.40 years. Group B contained 
206 cases in whom the disease did not progress to chron-
ic severe hepatitis B; 147 were male (71.36%), the average 
age was 35.49 ± 10.09 years, and the average course of ill-
ness was 4.23 ± 2.32 years. There was no significant differ-
ence in sex, age, or course of illness between the groups 
(P > 0.05). There was no significant difference in ALT, HBV 
DNA, or HbeAg-positive rate between groups (P >0.05) 
on the second day of admission (Table 1). The two groups 
were comparable in every aspect. Thirty healthy blood 
donors were enrolled as controls; 22 were male (73.33%), 
and the average age was 35.18 ± 7.01 years.
3.2. Treatment Methods
Both groups were treated with 200-mg silybin meglu-
mine tablets (Jiangsu Zhongxing Pharmaceutical) orally 
three times daily to protect the liver. For patients whose 
disease deteriorated, antiviral treatments were given af-
ter the laboratory tests when indicated. For those whose 
disease did not progress into severe hepatitis by Day 20 
after admission, antiviral therapy was given when the 
therapy was indicated.
3.3. Prothrombin Time (Activity)
Prothrombin time was measured by magnetic bead 
method (reagents and ACL-200 were purchased from 
Coulter, USA).
ALT a, u/L TBIL a, μmol/L ALB a, g/L HBVDNA a, log10 Copies/mL HBeAg a Positive, No. (%)
Group A, (n = 49) 426.35 ± 182.31 38.25 ± 22.17 41.95 ± 3.31 5.58 ± 0.76 29 (59.18)
Group B, (n = 206) 423.61 ± 190.91 37.88 ± 21.01 42.03 ± 1.42 5.59 ± 0.81 132 (64.08)
t value  0.115 0.146 0.273 0.113 χ2 = 0.409
P value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Table 1. Comparison of ALT, Total Bilirubin (TBIL), Albumin (ALB), HBV DNA and HBeAg Positive Rate between Group A and Group B at Baseline (mean ± SD)
a Abbreviations: ALB, albumin; ALT, alanine aminotransferase; HBeAg; hepatitis B e antigen ; HBVDNA, hepatitis B virus DNA; TBIL, total bilirubin
3.4. HBV Markers and HBV DNA
HBV markers (HBsAg, anti-HBs, HBeAg, anti-HBe, and 
anti-HBc) were measured by 1235 time-resolved fluores-
cence method; the reagents were purchased from Xinbo, 
Shanghai. HBV DNA was assayed by real-time fluores-
cence quantitative PCR; the reagents were purchased 
from Kehua, Shanghai.
3.5. Identification of HLA-A2 Allotypes
Fresh blood samples (100 μL) that were treated with 
heparin sodium were loaded into test and control tubes. 
After adding 10 μL HLA-A2-PE and the same type control, 
the tubes were incubated at room temperature for 30 
min in the dark and analyzed on a Beckman-Coulter 3XL 
after hemolysis. Reagents were purchased from Proim-
mune, UK.
3.6. HBV-Specific CTL Test
HBV-specific CD8+ T cells were measured by HLA-peptide 
tetramer flow cytometry, the principle of which is as fol-
lows (3): The tetramer is labeled with phycoerythin (PE), 
and CD8+ T cells from peripheral blood that are specific 
for an epitope identify and bind short peptides in the 
antigen channel through the T cell receptor (TCR); these 
CD8+ T cells are detected by FITC-labeled anti-CD8, and 
HBV antigen-specific CD8+ T cells are detected by dual-
Figure 1. Flow Cytometry of HBV Specific CTL
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color flow cytometry. (Figure 1)
Flow cytometry was performed as follows: 10 μL PE-
labeled HLA-peptide tetramer, anti-CD8-FITC, CD3-PC5, 
and 1 μL HBV core 18-27 antigenic peptide were loaded 
into test tubes; 100 μL heparin anti-coagulated blood was 
added and mixed well, and the tubes were incubated at 
room temperature for 20 min in the dark. After hemoly-
sis and rinse steps, the samples were analyzed on a flow 
cytometer. A parallel control (without antibody to the 
antigenic peptide) was also run. Five thousand CD8+ cells 
were counted, gating on CD3+ lymphocytes, and CD8+ 
CTLC CD4+ CD8+ CD4+/CD8+ Non-Specific CTL NK Cells
CHB, (n = 255) 65.78 ± 2.76 33.51 ± .23 27.58 ± 90 1.23 ± 0.11 17.79 ± 1.80 12.55 ± .87
Healthy controls, (n = 30) 68.83 ± 5.51 37.21 ± 6.09 25.13 ± 4.78 1.54 ± 0.43 15.83 ± 4.99 15.04 ± 4.17
t value 4.991 6.552 5.131 8.679 4.261 5.818
P value < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Table 2. Comparison of T Cell Subgroup, Non-Specific CTL a and NK a Cells between 255 CHB Patients and Normal Controls (mean ± SD) at Baseline
a Abbreviation: CTL, cytotoxic T lymphocyte; NK, natural killer
CD3+ CD4+ CD8+ CD4+/CD8+ Non-Specific CTL NK Cells
Group A, (n = 49)
Value, mean ± SD 65.01 ± 1.27 30.61 ± 1.67 30.09 ± 1.21 1.02 ± 0.05 20.24 ± 1.57 10.33 ± 1.93
Healthy controls, mean ± SD (n = 30) 68.83 ± 5.51 37.21 ± 6.09 25.13 ± 4.78 1.54 ± 0.43 15.83 ± 4.99 15.04 ± 4.17
t value 4.315 6.591 6.351 7.662 5.207 6.816
P value < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Group B, (n = 206)
Value, mean ± SD 65.83 ± 3.07 34.23 ± 1.71 26.95 ± 1.51 1.28 ± 0.06 17.18 ± 1.28 13.08 ± 1.41
Healthy controls, mean ± SD (n = 30) 68.83 ± 5.51 37.21 ± 6.09 25.13 ± 4.78 1.54 ± 0.43 15.83 ± 4.99 15.04 ± 4.17
t value 4.255 5.311 3.997 7.367 2.989 5.078
P value < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Table 3. Comparison of Baseline T Cell Subgroup, Non-Specific CTL a and NK a Cells between Group A and Group B with Normal Controls (mean ± SD)
a Abbreviation: CTL, cytotoxic T lymphocyte; NK, natural killer
and HLA-peptide tetramer double-positive cells were 
counted as HBV-specific CD8+ cells, expressed as the per-
centage of total CD8+ cells. All reagents were purchased 
from Beckman Coulter.
3.7. T Cell Subgroup, Nonspecific CTLs, and NK Cells
EDTA-K2 anticoagulated fresh blood (100 μl) was load-
ed into test and control tubes, and 10 μL of monoclonal 
antibody (anti-CD3, anti-CD4, anti-CD8, anti-CD28, and 
anti-CD16 + 56; Beckman Coulter) and parallel nonspe-
cific controls were added, respectively. The tubes were in-
cubated at room temperature for 15 min in the dark and 
analyzed by flow cytometry after hemolysis. (Figure 2)
3.8. Statistical Analysis
SPSS 12.0 was used for the statistical analysis. Chi-square 
test was applied for categorical data, and t-test was used 
for numerical data, which were expressed as mean ± 
standard deviation (SD). The differences were considered 
significant when P < 0.05.
4. Results
4.1. Deterioration of CHB into Chronic Severe Hepatitis B
In 49 of the 255 CHB patients (19.22%), the disease 
progressed into early-stage chronic severe hepatitis B 
(Group A) an average of 10.06 ± 1.73 days after admission, 
with such symptoms as lassitude, decreased appetite, 
nausea, and vomiting; the mean TBIL was 338.51 ± 59.31 
μmol/L, and prothrombin activity was 35.25 ± 2.91%. In the 
remaining 206 cases (80.78%), the disease did not prog-
ress into severe hepatitis B (Group B).
Figure 2. Flow Cytometry of Nonspecific CTL
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CD3+ CD4+ CD8+ CD4+/CD8+  Non-specific CTL HBV specific CTL NK cells
Group A, 
(n = 49)
65.01 ± 1.27 30.61 ± 1.67 30.09 ± 1.21 1.02 ± 0.05 20.24 ± 1.57 0.32 ± 0.02 
(n = 25)
10.33 ± 1.93
Group B, 
(n = 206)
65.83 ± 3.07 34.23 ± 1.71 26.95 ± 1.51 1.28 ± 0.06 17.18 ± 1.28 0.31 ± 0.03 
(n = 103)
13.08 ± 1.41
t value 1.678 12.761 12.311 19.997 12.971 0.881 11.364
P value > 0.05 < 0.01 < 0.01 < 0.01 < 0.01 > 0.05 < 0.01
Table 4. Comparison of Baseline T Cell Subgroup, HBV Specific CTL a, Non-Specific CTL and NK a Cells between Group A and Group B (mean ± SD)
a Abbreviation: CTL, cytotoxic T lymphocyte; NK, natural killer
4.2. Comparison of T Cell Subgroups, Nonspecific CTLs, 
and NK Cells between CHB Patients and Controls
The T cell subgroup, nonspecific CTL, and NK cell levels 
on Day 2 of admission (baseline) in the 255 CHB patients 
and 30 healthy controls are listed in Table 2. The mean 
CD3+, CD4+, CD4+/CD8+, and NK cell levels in the patients 
with CHB were significantly lower versus the control 
group (P < 0.01), and the mean CD8 and nonspecific CTL 
levels in CHB patients were significantly higher com-
pared with controls (P < 0.01). Table 3 shows the compari-
son of T cell subgroups, nonspecific CTLs, and NK cells at 
baseline between Groups A and B. The mean CD3+, CD4+, 
CD4+/CD8+, and NK cell levels in Group A were significant-
ly lower than in the healthy control group (P < 0.01), and 
the mean CD8+ and nonspecific CTL levels in CHB patients 
were higher than in the healthy control group (P < 0.01).
The mean CD3+, CD4+, CD4+/CD8+, and NK cell counts in 
Group B were also significantly lower than in the control 
group (P < 0.01), and mean CD8+ and nonspecific CTL lev-
els in Group B were higher than in the healthy control 
group (P < 0.01).
4.3. Comparison of T Cell Subgroups, HBV-Specific CTL, 
Nonspecific CTLs, and NK Cells between Groups A and B
Of the 49 cases in Group A, 25 were positive for HLA-A2 
(51.02%); of the 206 cases of Group B, 103 were positive 
for HLA-A2 (50%). HBV-specific CTLs were measured only 
in HLA-A2-positive patients. T cell subgroup, HBV-specific 
CTL, nonspecific CTL, and NK cell levels at baseline in 
both CHB groups are listed in Table 4. The mean levels of 
CD4+, CD4+/CD8+ and NK cells in Group A were significant-
ly lower than in Group B (P < 0.01), and the mean CD8+ 
and nonspecific CTL levels in Group A were higher than 
in Group B (P < 0.01). Interestingly, there was no signifi-
cant difference in HBV-specific CTL response between the 
two groups of patients with CHB i.e. the HBV-specific CTL 
CD3+ CD4+ CD8+ CD4+/CD8+ Non-Specific CTL HBV Specific CTL NK Cells
Group A, 
(n = 49)
65.42 ± 2.13 28.25 ± 1.66 33.38 ± 1.51 0.85 ± 0.06 23.47 ± 1.77 0.33 ± 0.03 
(n = 25)
7.02 ± 1.45
Group B, 
(n = 206)
65.87 ± 3.15 34.17 ± 1.72 26.97 ± 1.44 1.27 ± 0.08 17.21 ± 1.55 0.30 ± 0.03 
(n = 103)
13.07 ± 1.98
t value  0.898 19.515 24.765 28.561 21.956 3.588 20.10
P value > 0.05 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Table 5. Comparison of T Cell Subgroup, HBV Specific CTL a ,Non-Specific CTL and NK a Cells between Group A after the Disease Progressed to Chronic Severe 
Hepatitis B and Group B 10 Days after Admission (mean ± SD)
a Abbreviation: CTL, cytotoxic T lymphocyte; NK, natural killer
CD3+ CD4+ CD8+ CD4+CD8+ Non-Specific CTL HBV Specific CTL NK Cells
Group A, (n = 49)
Baseline 65.01 ± 1.27 30.61 ± 1.67 30.09 ± 1.21 1.02 ± 0.05 20.24 ± 1.57 0.32 ± 0.02 (n = 25) 10.33 ± 1.93
After progress 65.42 ± 2.13 28.25 ± 1.66 33.38 ± 1.51 0.85 ± 0.06 23.47 ± 1.77 0.33 ± 0.03 (n = 25) 7.02 ± 1.45
t value 1.125 6.441 10.887 11.567 8.83 0.971 9.594
P value > 0.05 < 0.01 < 0.01 < 0.01 < 0.01 > 0.05 < 0.01
Group B, (n = 206)
Baseline 65.83 ± 3.07 34.23 ± 1.71 26.95 ± 1.51 1.28 ± 0.06 17.18 ± 1.28 0.31 ± 0.03 (n=103) 13.08 ± 1.41
10 d after admission 65.87 ± 3.15 34.17 ± 1.72 26.97 ± 1.44 1.27 ± 0.08 17.21 ± 1.55 0.30 ± 0.03 (n=103) 13.07 ± 1.98
t value 0.161 0.492 0.251 0.664 0.283 2.86 0.059
P value > 0.05 > 0.05 > 0.05 > 0.05 > 0.05 < 0.01 > 0.05
Table 6. Comparison of T Cell Subgroup, HBV Specific CTL a, Non-Specific CTL and NK a Cells in Group A after the Disease Progressed to Chronic Severe Hepati-
tis B, Group B 10 Days after Admission and the baseline of both Groups (mean ± SD)
a Abbreviation: CTL, cytotoxic T lymphocyte; NK, natural killer814
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response did not increase in the 49 patients before their 
disease deteriorated (P > 0.05).
The nonspecific and HBV-specific cellular immunity 
parameters, determined on an average of 10 days after 
admission—i.e. after the disease in 49 cases progressed to 
severe liver disease—are listed in Table 5. The mean CD4+, 
CD4+/CD8+, and NK cell levels in Group A were significant-
ly lower than in Group B (P < 0.01), and the mean CD8+ 
and nonspecific CTL values in Group A were significantly 
higher than in Group B (P < 0.01). However, the HBV-spe-
cific CTL count was higher in Group A than in Group B 
(0.33 vs. 0.30) (P < 0.01).
4.4. Comparison of T Cell Subgroups, HBV Specific CTLs, 
Nonspecific CTLs, and NK Cells in Group A before and 
after Disease Progression to Severe Liver Disease
The T cell subgroup, HBV-specific CTL, nonspecific CTL, 
and NK cell levels in Group A before and after progres-
sion to chronic severe hepatitis B and Group B at base-
line and 10 days after admission are listed in Table 6. After 
deterioration of the disease, the mean values of CD4+, 
CD4+/CD8+, and NK cell levels decreased significantly (P < 
0.01), the change in CD3+ T cells was not significant (P > 
0.05), and the mean values of CD8+ and nonspecific CTL 
increased significantly (P < 0.01), whereas the HBV-specif-
ic CTL response did not show any significant change (P > 
0.05). All 7 parameters of cellular immunity in Group B 
did not show any significant changes between baseline 
and 10 days after admission (P > 0.05), except for a de-
crease in HBV-specific CTL responses (Table 6).
5. Discussion
The results of the present study show that there were 
significant increases in peripheral blood CD8+ cells and 
nonspecific CTLs in patients with chronic severe hepa-
titis B (early stage), suggesting that the immunological 
pathogenesis of chronic severe hepatitis B is related to 
significant increases in CD8+ and nonspecific CTL levels 
and these increases can predict that CHB will progress to 
severe hepatitis. In China, most cases of severe chronic 
hepatitis result from HBV infection. Chronic severe hepa-
titis B progresses rapidly and is difficult to manage. The 
mortality rate of severe chronic hepatitis is over 50% 
(4, 5), and 36.9% of cases with chronic severe hepatitis 
occurred on the basis of CHB (6). Preventing or halting 
the deterioration can obviously improve the prognosis 
of CHB patients. To do so, it is necessary to determine or 
predict in which CHB patients the disease will progress 
to severe hepatitis so that corresponding measures can 
be taken. It is commonly believed that the pathogenesis 
of hepatitis B is the consequence of cellular immune re-
sponses that cause damage to the liver, although they are 
aimed primarily at removing HBV from the liver tissue 
(1). The exacerbation of chronic hepatitis is mainly due 
to the action of CD8+ CTLs, which kill liver cells directly 
through double identification of major histocompatibil-
ity complex (MHC) antigen and hepatitis B antigen (7).
In an animal model of severe hepatitis, Ando et al. dem-
onstrated that CD8+ cells cause the necrosis of many liver 
cells through cellular immunity (8). However, recent 
studies suggest that cellular immune mechanisms for 
eliminating HBV can be divided into specific and non-
specific responses (3). Specific cellular immune respons-
es of the body that are induced by the virus may be an 
important factor in eliminating the virus (9). There are 
two routes for virus-specific CTLs to remove HBV: cyto-
toxic and noncytolytic (10). In the noncytotoxic route, 
specific T lymphocytes only clear the virus from target 
cells, without injuring the target cell itself. In the process 
of clearing the virus by specific T cells, the noncytolytic 
route may play a more important role (11). Nonspecific 
cellular immunity is relatively weak in clearing HBV, but 
it may cause liver cell injuries in the process (12-14). Thus, 
we studied the changes in HBV-specific and nonspecific 
cellular immune responses before and after CHB pro-
gressed to chronic severe hepatitis B to provide evidence 
for the rational treatment, control, and prevention of de-
terioration of CHB.
In this study, CD3+, CD4+, CD4+:CD8+ ratio, and NK cell 
levels in 255 CHB patients were lower than in healthy 
controls (P < 0.01). CD8+ and nonspecific CTL levels were 
higher than in healthy controls (P < 0.01), which clearly 
indicates that cellular immunity in CHB patients is dys-
functional. The levels of CD4+ and NK cells of Group A (i.e., 
patients whose disease progressed to severe hepatitis) 
were lower than in the same patients on Day 2 (baseline) 
of admission (P < 0.01), which were lower than Group B 
baseline levels (P < 0.01), and the latter was lower than in 
the healthy control group (P < 0.01). These levels in Group 
A after progression to severe hepatitis were lower than in 
Group B 10 days after admission (P < 0.01). The levels of 
CD8+ and nonspecific CTLs in Group A after progression 
to severe hepatitis were higher than in the same group at 
baseline (P < 0.01), which were higher than the baseline 
levels in Group B (P < 0.01), and the latter was higher than 
in the healthy control group (P < 0.01). These parameters 
in Group A after deterioration to severe hepatitis were 
higher than in Group B 10 days after admission (P < 0.01).
In patients with chronic severe hepatitis B, CD4+ levels 
decrease and CD8+ levels increase (15). The CD8+ T cells 
that increase in patients with viral hepatitis are mainly 
CTL (15). Our study also demonstrates this phenomenon. 
HBV-specific CTL levels were not associated with dete-
rioration of the disease, since there was no significant 
difference in specific CTL levels between Groups A and B 
at baseline (P > 0.05) or in Group A before and after the 
disease progressed to severe hepatitis (P > 0.05). On the 
other hand, in patients with severe chronic hepatitis, NK 
cells may migrate to the target cells via chemotaxis and 
exert antiviral actions or kill liver cells directly, which 
can reduce NK cell numbers (16). This study shows that 
peripheral blood CD8+ and nonspecific CTLs in patients 
with chronic severe hepatitis B (early stage) increased 
significantly compared with CHB patients whose disease 815
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did not deteriorate, whereas HBV-specific CTLs did not 
change, which suggests that the immunological patho-
genesis of chronic severe hepatitis B is associated with a 
significant increase in CD8+ and nonspecific CTLs. In ad-
dition, before the disease in Group A patients progressed 
to severe hepatitis, CD8+ and nonspecific CTL levels had 
already increased markedly. Therefore, significant in-
creases in CD8+ and nonspecific CTL levels in CHB pa-
tients may predict deterioration of CHB to severe hepa-
titis. When the deterioration occurs, the symptoms of 
patients worsen. Glucocorticoids should be considered 
in the treatment of such patients to decrease the exces-
sively high levels of CD8+ T cells and nonspecific CTLs 
(17) and prevent CHB patients from developing chronic 
severe hepatitis.
The weaknesses of this study are that we did not test 
cellular immunity in the liver tissue of patients, the 
follow-up period was too short, and the sample size was 
not large enough. Larger-scale, better-designed studies 
are needed for further exploration of the mechanisms of 
deterioration of chronic hepatitis B. In conclusion, this 
study shows that the deterioration of CHB may be asso-
ciated with significantly increased levels of CD8+ T cells 
and nonspecific CTLs, which may predict deterioration 
of CHB.
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